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In children with childhood-onset growth hormone deficiency, replacement GH therapy
is effective in normalizing height during childhood and achieving adult height within the
genetic target range. GH has further beneficial effects on body composition and metab-
olism through adult life. The transition phase, defined as the period from mid to late
teens until 6–7 years after the achievement of final height, represents a crucial time for
reassessing children’s GH secretion and deciding whether GH therapy should be continued
throughout life. Evidence-based guidelines for diagnosis and treatment of growth hormone
deficient children during transition are lacking. The aim of this review is to critically review
the up-to-date evidence on the best management of transition patients in order to ensure
the correct definitive diagnosis and establish the appropriate therapeutic regimen.
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INTRODUCTION
The main effect of GH therapy in childhood is to stimulate
linear growth: therefore the primary objective of GH replace-
ment therapy in growth hormone deficient (GHD) children is
to achieve adult height within the genetic target range. In addi-
tion, GH plays a key role in the regulation of body composi-
tion and metabolism and its deficiency in adulthood has been
associated with reduced lean body mass and bone mineral den-
sity (BMD), increased visceral adiposity, abnormal lipid profile,
decreased muscle strength, cardiovascular risk, and impaired qual-
ity of life (Rosén and Bengtsson, 1990; Cuneo et al., 1992, 1993;
Rosén et al., 1993; de Boer et al., 1994, 1995; Weaver et al., 1995;
Attanasio et al., 1997; Johansson et al., 2004). These non-growth
promoting effects of GH are considered so important for body
homeostasis to require lifelong GH administration in subjects with
permanent GHD (Molitch et al., 2006). As many subjects are no
longer GH-deficient when retested at the end of linear growth,
the correct reassessment of childhood-onset GHD (CO-GHD) is
crucial for selecting patients who need lifelong GH therapy.
Transition phase has been defined as the period of life starting
in late puberty and ending with full adult maturation (i.e., from
mid to late teenage years until 6–7 years after achievement of final
height) (Gordon et al., 1991; Matkovic et al., 1994; Clayton et al.,
2005).
During transition GH is effective in maintaining body pro-
portions and metabolic balance. In addition, significant psy-
chosocial adjustment takes place during this time frame. There-
fore, CO-GHD patients should not be declared adults as soon
as they achieve adult height, but should receive specific care
in the context of a transition program managed by pediatric
or adult endocrinologists experienced in the management of
hypopituitarism and GHD.
PECULIARITIES OF GH DEFICIENCY FROM CHILDHOOD TO
ADULTHOOD
Features of adult GHD syndrome are summarized in Table 1.
It has been reported that GH replacement therapy in adult-
hood normalizes metabolism and body composition (Molitch
et al., 2006), and may improve the quality of life of GHD patients
(McGauley, 1989).
Transition years represent an important phase of growth
process when somatic development reaches its completion. Several
studies have tried to evaluate the consequences of either withdraw-
ing or continuing GH therapy in transition subjects, often arriving
at conflicting results in terms of both magnitude of response and
dose-effect relationship (Table 2).
In most studies, GH treatment in the transition phase increases
lean body mass and reduces fat mass, especially in males, with still
conflicting data regarding the dose-response (Nørrelund et al.,
2000; Vahl et al., 2000; Underwood et al., 2003; Attanasio et al.,
2004; Carroll et al., 2004). However, similar effects are observed
when GH replacement is resumed after a variable off-therapy time.
These results have been questioned by Mauras’ study on a popula-
tion of 58 CO-GHD adolescents who were randomized to receive
either GH or placebo for 2 years (Mauras et al., 2005). No differ-
ences in body composition, lipid and carbohydrate metabolism,
BMD, cardiac function, muscle strength, or quality-of-life were
observed. However, the fact that this study comprised a higher
percentage of patients with idiopathic/isolated GHD than previ-
ous studies, may account for the lack of metabolic effects induced
by GH therapy. GH deficiency during the transition phase may
reduce BMD thus increasing the risk of osteoporosis and frac-
tures (Matkovic et al., 1994; Saggese et al., 1996; Johannsson
et al., 1999; Attanasio et al., 2002; Drake et al., 2003; Shalet et al.,
2003; Underwood et al., 2003). Therefore, Shalet (2006) proposed
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Table 1 | Features of growth hormone deficiency (GHD) in adult
patients.
Features of GHD adult patients
Reduced lean body mass and increased visceral adiposity
Reduced bone mineral density with increased risk of fractures
Reduced IGF-I levels
Decreased muscle strength and exercise capacity
Diminished quality of life (less cognitive function, decreased of well-being)
Abnormal serum lipid profile (increased total cholesterol, LDL cholesterol,
triglycerides, lipoprotein A, apolipoprotein B; decreased HDL cholesterol)
Lower cardiac function, impaired left ventricular performance, and
increased prevalence of cardiovascular disease
to continue GH treatment, without any withdrawal, to allow the
attainment of peak bone mass. On the contrary, the study by
Mauras et al. (2005) has shown no benefit of GH therapy con-
tinuation on BMD. Högler and Shaw (2010) support the idea that
isolated CO-GHD is not associated with the risk of fractures and
low bone density and that routine DXA measurements should
not be recommended for children or young adults with isolated
CO-GHD.
There is moderate evidence that insulin sensitivity increases
after discontinuation of GH therapy, whereas no change or only a
moderate increase of fasting insulin values is observed in subjects
who continue therapy (Nørrelund et al., 2000; Underwood et al.,
2003; Carroll et al., 2004). However, Mauras et al. (2005) found no
changes in glucose metabolism related parameters in GH-treated
vs. placebo-treated and control subjects.
GH treatment seems to improve the lipid profile of GHD
patients (Vahl et al., 2000). A deterioration of lipid status (i.e.,
increased LDL and reduced HDL cholesterol levels) has been
reported in GHD adolescents after discontinuation (Johannsson
et al., 1999; Colao et al., 2002; Attanasio et al., 2004). Koltowska-
Häggström et al. (2010) suggest that a longer GH off-therapy
period is associated with a worse lipid profile, proposing that the
sooner GH treatment is resumed, the better is the metabolic out-
come. On the contrary, Carroll et al. (2004) showed no changes in
lipid profile after discontinuation of GH.
In conclusion, there are conflicting data on the necessity to
continue GH therapy during transition without interruption. The
majority of studies suggest that the continuation of GH treatment
would prevent the onset of metabolic alterations and deteriora-
tion of body composition, whereas the impact of GH treatment
on quality of life and psychological well-being remains to be
established.
RETESTING GH SECRETION: LIGHTS AND SHADOWS
More than two thirds of children diagnosed as GH insufficient
show normal GH response when retested at the end of growth
(Tauber et al., 1997; Maghnie et al., 1999; Attanasio et al., 2002).
In particular, there is a good chance of recovering a normal GH
secretion for patients with idiopathic GHD as well as for subjects
with isolated or partial GHD (Tauber et al., 1997; Maghnie et al.,
1999).
Patients with known mutations or irreversible structural lesions
with multiple pituitary hormone deficits (MPHD) are likely to
have permanent GHD, though there may be subjects with MPHD
with normal GH response at retesting (de Boer and van der Veen,
1997; Tauber et al., 1997; Shalet et al., 1998; Maghnie et al., 1999).
Normalization of GH secretion is highly unlikely in patients who
underwent surgery and/or cranial irradiation and never occurs
in patients operated for craniopharyngioma (Tauber et al., 1997;
Maghnie et al., 1999; Leger et al., 2005).
The possible causes of recovering a normal GH response to
stimulation tests are summarized in Table 3 (Cacciari et al., 1992,
1994; Aimaretti et al., 2000; Maghnie et al., 2001, 2002; Radetti
et al., 2007).
In CO-GHD teenagers, pituitary function is re-evaluated at the
end of linear growth, as defined by growth velocity of less than
1.5–2 cm/year or a bone age of at least 14.5 years in females and at
least 16.5 years in males (Clayton et al., 2005; Attanasio and Shalet,
2007). It is widely accepted the necessity of a GH wash out period
prior to retesting, to avoid false positive results. Nevertheless, the
shortest wash out time to get reliable retesting data is still unde-
fined. An interval of 1–3 months was considered acceptable by the
GH Research Society (Growth Hormone Research Society, 2000;
Geffner, 2003; Molitch et al., 2006).
A proposed workup of CO-GHD patients at the end of growth
is summarized in Figure 1 (Clayton et al., 2005). In brief, a single
measurement of baseline IGF-I levels in patients with high likeli-
hood of permanent GHD as a consequence of genetic causes, struc-
tural hypothalamic-pituitary anomalies, acquired hypothalamic-
pituitary disease, and irradiation of the hypothalamus-pituitary
area could be adequate to establish the final diagnosis. IGF-I val-
ues less than −2 SDS indicate persistent GHD, whereas values
higher than−2 SDS, should prompt to perform a GH provocative
test, a subnormal response confirming GHD diagnosis. In patients
with low likelihood of permanent GHD, such as those with isolated
idiopathic GHD, both GH provocative test and IGF-I assessment
should be performed to achieve the final diagnosis. If both para-
meters are normal the condition of GHD can be excluded. If both
parameters are low, GHD diagnosis is confirmed. Finally, in case
of conflicting results re-evaluation of the case is required.
TESTING THE TESTS
Since it is well known that GH is secreted by the pituitary gland
in a pulsatile pattern, provocative tests are needed to investigate
pituitary GH secretion. There are many different GH pharmaco-
logical stimulation tests, each of them showing both advantages
and limitations. The choice of the suitable GH provocative test
is mainly based on the balance between reliability and safety.
Although, an optimal GH stimulation test to be used in transi-
tion has yet to be established, the insulin tolerance test (ITT) has
been suggested to have the best efficacy/safety ratio if performed in
experienced endocrine units. ITT is considered as the “gold stan-
dard” for GHD diagnosis in adults, and allows the assessment of
both GH secretion and the hypothalamus-pituitary-adrenal axis
function (Geffner, 2003; Styne, 2003). However, ITT may pro-
voke severe hypoglycemia and is contraindicated in patients on
anticonvulsant drugs, with coronary heart disease or with adrenal
insufficiency (Clayton et al., 2005; Molitch et al., 2006).
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Table 3 | Possible causes of recovering a normal GH response to stimulation tests.
Possible causes of GH response recovering to stimulation tests at the end of linear growth
Transient GH deficiency
Changes in diagnostic criteria or lack of reproducibility in GH stimulation testing
False positive response at the time of diagnosis in children with short stature or pubertal delay
Neurosecretory dysfunction (characterized by a normal response to provocative tests and reduced spontaneous release)
Improvement in hypothalamic-pituitary function after puberty
Different response to stimulation tests due to:
Type of stimulation test
Age
BMI
Disease duration
Number of pituitary hormone deficiencies
Pituitary abnormalities
CO-GHD teenagers with growth velocity< 1.5/2 cm/year or with bone age  
of 14.5 years in females and 16.5 years in males 
GH wash out period 
(1-3 months) 
Low likelihood of 
permanent GHD  
GH provocative test + 
Baseline IGF-1 levels  
Abnormal 
results 
GH therapy 
Conflicting 
results 
Normal  
results 
Follow-up 
GHD 
excluded 
High likelihood of 
permanent GHD  
Baseline IGF-1 levels 
>-2 SDS 
GH provocative  test 
-2SDS 
Diagnostic 
Abnormal 
result 
Normal  
result 
GHD 
excluded 
FIGURE 1 |The proposed workup for assessing transition patients with growth hormone deficiency. From a consensus statement issued by the
European Society for Pediatric Endocrinology (Clayton et al., 2005).
An alternative test is the combined stimulation with Growth
Hormone Releasing Hormone and arginine (GHRH+Arg). It
shows excellent sensitivity and specificity both in childhood
and in adulthood, assuming appropriate cut-off limits (Cor-
neli et al., 2007; Giacomozzi et al., 2012) but its reliabil-
ity is uncertain in patients with hypothalamic impairment.
Therefore, a normal GH response to GHRH+Arg test in
a patient with ascertained hypothalamic alterations should
induce suspicion for a false negative result. In case of discrep-
ancy between the response to whatever GH stimulation test
and IGF-I concentrations, the diagnosis should be critically
reconsidered.
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Glucagon, arginine, GHRH, and clonidine provocative tests
have been reported to be less accurate in diagnosing GHD in tran-
sition, in that no cut-off limits have been established (Styne, 2003;
Clayton et al., 2005; Gasco et al., 2008).
Although ITT and GHRH+Arg tests have been partly validated
in transition, the available data are scarce and, at the moment, their
use is not driven by a firmly established evidence-based approach.
There is still controversy about the cut-off values to be used to dis-
criminate between normal and abnormal GH response in patients
during the transition phase. The ITT cut-off value used in adult-
hood, i.e., a GH peak less than 3 ng/ml, seems to be too restrictive as
the highest GH response to provocative test occurs in late puberty
(Clayton et al., 2005).
Bonfig et al. (2008) have reported the highest accuracy of ITT
with a cut-off of 5 ng/ml,whereas Secco et al. (2009) have suggested
a GH peak of 5.62 ng/ml as the best discriminator in patients with
high likelihood for permanent GHD. Maghnie et al. (2005) have
reported that a GH peak of 6.1 ng/ml has a sensitivity of 96%
and a specificity of 100%, concluding that a cut-off of less than
5 ng/ml is too restrictive for the diagnosis of permanent GHD in
the transition phase, being burdened by a high rate of false negative
results.
The cut-off values in GHRH+Arg test are even more debated.
The same value used in adults, i.e., GH peak of 9 ng/ml, was ini-
tially proposed. More recently, the same GH peak value used in
childhood, i.e., 19 ng/ml, has been reported to achieve 100% sen-
sitivity and 97% specificity. However, this cut-off value has been
validated in a relatively small cohort of patients. Moreover, this
reference was obtained in lean subjects and needs to be validated
in overweight and obese patients. Obesity is associated with both
decreased basal and pulsatile release of GH and lower GH response
to provocative tests. Therefore, obesity related parameters, such as
waist circumference, trunk fat, and abdominal visceral adipose tis-
sue, should be considered in order to establish appropriate cut-off
values (Makimura et al., 2008).
In conclusion, many factors can influence the definition of cut-
off limits in transition, such as the different etiology of GHD and
the age at retesting, yielding conflicting results. To date, robust
data concerning reference values for stimulation tests in healthy
adolescents are lacking.
IGF-I and IGFBP-3 may represent helpful markers of GH secre-
tory status (Cianfarani et al., 2005). It has been reported that in
transition patients the use of a cut-off value of −2 SDS accord-
ing to age and sex-related IGF-I levels would miss more than one
third of GHD subjects,−2 SDS showing a sensitivity of 62%,−1.7
SDS of 77%, and−1.3 SDS of 87% (Maghnie et al., 2005; Corneli
et al., 2007). However, most of the reference values used in these
studies was taken from the assay kit sheet without in house valida-
tion on a representative control population. Furthermore, it is well
known that a remarkable variability among different assay exists
due to differences in antibody specificity and/or pre-analytical
sample preparation strategies to remove binding protein inter-
ferences. This inter-assay variability affects assay standardization
(Clemmons, 2011). Recently, high resolution mass spectrometry
has been validated for quantitative analysis of IGF-I. This approach
offers the advantage of being carried out under conditions that can
be tuned to preserve or eliminate biologically relevant interactions
(Bystrom et al., 2012). The publication of IGF-I reference values
up to the age of 18 years opens avenue for the correct use of IGF-I
measurement (Brabant et al., 2003; Elmlinger et al., 2004; Bedogni
et al., 2012).
Although IGFBP-3 measurement shows a high specificity in
diagnosing GHD (about 100%), sensitivity is poor (about 30%),
due to a number of pitfalls which limit reliability and usefulness
in clinical practice (Cianfarani et al., 2005).
Magnetic resonance imaging (MRI) is another helpful tool
to establish the diagnosis of permanent GHD. It is however
worth remembering that not all neuroradiological abnormalities
detected at the time of initial diagnosis are indicative of a perma-
nent GH deficiency. While hypothalamic-pituitary disconnections
are often associated with persistent deficiency, pituitary hypoplasia
(Maghnie et al., 1999; Radetti et al., 2007) and ectopic posterior
pituitary may be associated with a normalization of GH secretion
(Di Iorgi et al., 2007).
DECIDING ON THE OPTIMAL GH REPLACEMENT DOSE IN
TRANSITION: A LEAP IN THE UNKNOWN
Another challenge in the transition phase is to establish the opti-
mal dose of GH for achieving normal adult height and optimal
metabolic profile (Clayton et al., 2005). The usual GH replacement
dose for children (25–35µg/kg/day) and adults (100–300µg/day)
seems in fact inappropriate in transition (Growth Hormone
Research Society, 2000; Molitch et al., 2006). A dose of 200–
500µg/day, with the higher doses in girls on estrogen replacement
therapy, has been suggested (Clayton et al., 2005). Thereafter,
the dosage may be progressively increased up to 400–500µg/day.
Treatment should be tailored to meet the individual requirements
on the basis of the clinical response and serum IGF-I concen-
trations, which should be kept between 0 and +2 SDS (Clayton
et al., 2005). A good clinical response should induce to maintain
the same GH dose even in presence of sub-optimal IGF-I levels
(Clayton et al., 2005).
CONCLUSION: DOES TRANSITION REALLY EXIST?
Due to the existing conflicting data on both diagnosis and treat-
ment of GHD patients during transition, it has to be pointed
out that many of the current approaches are based on arbitrary
assumptions rather than on evidence-based medicine. The same
definition of transition leaves room to ambiguity. There is no bio-
logical basis for considering GHD individuals during a so wide
time span under the same label. The different individuals enter
puberty at different times; all the more GHD patients have differ-
ent rates of biological and psychological maturation. Stimulation
test cut-offs, GH doses, and responses to GH therapy during tran-
sition may be influenced by age, time elapsed from puberty, and
underlying diagnoses. It is surprising that in an epoch of indi-
vidualized medicine and pharmacogenomics, a so simplistic and
all-inclusive definition is being still used. Moreover, do we really
need that? The diagnosis of permanent GHD should be based on a
comprehensive clinical, anthropometric, biochemical, endocrine,
and neuroradiological approach rather than arbitrary cut-off lab-
oratory values. Finally, GH dose should be tailored to meet indi-
vidual requirements for optimizing growth, body composition,
bone mineralization, and metabolic homeostasis.
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